Superstring Capital Acquires Shares in Vir Biotechnology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2026
0mins
Source: NASDAQ.COM
- Share Acquisition: Superstring Capital acquired 730,548 shares of Vir Biotechnology in Q1, with an estimated transaction value of $5.82 million, reflecting confidence in the company's future developments.
- AUM Growth: This transaction resulted in a 4.16% increase in Superstring Capital's 13F reportable AUM, indicating that its investment strategy in the biotechnology sector is yielding positive results.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and cash equivalents at the end of Q2, and expects to receive an additional $315 million from its collaboration with Astellas, enhancing its funding for future R&D.
- Clinical Progress: Vir's chronic hepatitis program showed that 88% of patients achieved undetectable virus levels through Week 96 in Phase 2 trials, with pivotal Phase 3 data expected in Q4 2026, potentially leading to significant breakthroughs for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VIR
Wall Street analysts forecast VIR stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.550
Low
12.00
Averages
15.60
High
24.00
Current: 9.550
Low
12.00
Averages
15.60
High
24.00
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Superstring Capital Acquires New Position in Vir Biotechnology
- New Investment Position: Superstring Capital Management disclosed a new position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026, with an estimated transaction value of $5.82 million, indicating confidence in the company's future developments.
- Increased Position Value: By quarter-end, Superstring's position in Vir was valued at $6.55 million, reflecting both trading activity and price appreciation, which underscores investor recognition of the company's potential.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and investments at the start of Q2, while also expecting to receive an additional $315 million from its collaboration with Astellas, enhancing its financial flexibility to support future R&D.
- Significant Clinical Progress: Vir's chronic hepatitis delta program showed encouraging Phase 2 data, with 88% of evaluated patients achieving undetectable virus levels by Week 96, and the company anticipates Phase 3 data from its lead study in Q4 2026, further boosting market confidence.
See More
Superstring Capital Acquires Shares in Vir Biotechnology
- Share Acquisition: Superstring Capital acquired 730,548 shares of Vir Biotechnology in Q1, with an estimated transaction value of $5.82 million, reflecting confidence in the company's future developments.
- AUM Growth: This transaction resulted in a 4.16% increase in Superstring Capital's 13F reportable AUM, indicating that its investment strategy in the biotechnology sector is yielding positive results.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and cash equivalents at the end of Q2, and expects to receive an additional $315 million from its collaboration with Astellas, enhancing its funding for future R&D.
- Clinical Progress: Vir's chronic hepatitis program showed that 88% of patients achieved undetectable virus levels through Week 96 in Phase 2 trials, with pivotal Phase 3 data expected in Q4 2026, potentially leading to significant breakthroughs for the company.
See More
SB Investment Advisers Reduces Stake in Vir Biotechnology
- Share Reduction Details: SB Investment Advisers reported a sale of 2,168,884 shares of Vir Biotechnology in its SEC filing dated May 15, 2026, with an estimated trade value of $17.28 million, indicating a strategic adjustment in its investment approach.
- Market Performance Analysis: As of May 15, 2026, Vir Biotechnology's stock price stood at $8.79, reflecting a 93% increase over the past year, significantly outperforming the S&P 500's approximate 25% gain, showcasing the company's robust market performance.
- Financial Overview: Vir Biotechnology has a market capitalization of $1.48 billion, with a trailing twelve-month revenue of $64.7 million and a net loss of $442.72 million, indicating ongoing challenges in profitability, yet it maintains a strong liquidity position with $809.3 million in cash and investments.
- Strategic Development Dynamics: Despite trimming over 2 million shares, SB Investment Advisers still holds approximately $98 million in Vir, suggesting confidence in the company's long-term potential in oncology and hepatitis, particularly following significant advancements in its partnership with Astellas.
See More
Boxer Capital Increases Stake in Vir Biotechnology
- Share Acquisition: On May 15, 2026, Boxer Capital Management disclosed the purchase of 1,241,000 shares of Vir Biotechnology, valued at approximately $9.89 million, indicating increased confidence in the company's prospects.
- Stake Increase: This transaction raised Boxer Capital's stake in Vir Biotechnology to 2.2%, highlighting its significant interest in the company as reported in the 13F filing.
- Financial Performance: Vir Biotechnology's market value increased by $12.95 million in Q1 2026, despite a net income loss of $442.72 million; however, its stock price surged 100% over the past year, significantly outperforming the S&P 500's 25% increase.
- Future Outlook: Vir Biotechnology reported encouraging Phase 2 data in chronic hepatitis delta, with pivotal Phase 3 trials for its prostate cancer treatment expected in 2027, raising questions about its ability to achieve sustainable commercialization amidst investor scrutiny.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Vicki Sato Sells 22,000 Shares of Vir Biotechnology Stock
- Transaction Overview: Vicki Sato sold 22,000 shares of common stock for approximately $221,000 according to SEC Form 4, retaining 1,078,391 shares post-sale, valued at around $10.78 million, indicating her continued confidence in the company.
- Trading Plan: The sale was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, suggesting that Sato is engaging in routine portfolio management rather than reacting to market fluctuations.
- Ownership Proportion: This transaction represented 2% of Sato's direct holdings, leaving her with approximately 77.5% of her initial position, which underscores her long-term commitment and confidence in the company.
- Company Overview: Vir Biotechnology focuses on developing monoclonal antibodies and RNA-based therapeutics for infectious diseases like COVID-19 and HIV; despite a net loss of $125.7 million in Q1, the company holds $809.3 million in cash and investments, ensuring operational sustainability.
See More
Superstring Capital Acquires New Position in Vir Biotechnology
- New Investment Position: Superstring Capital Management disclosed a new position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026, with an estimated transaction value of $5.82 million, indicating confidence in the company's future developments.
- Increased Position Value: By quarter-end, Superstring's position in Vir was valued at $6.55 million, reflecting both trading activity and price appreciation, which underscores investor recognition of the company's potential.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and investments at the start of Q2, while also expecting to receive an additional $315 million from its collaboration with Astellas, enhancing its financial flexibility to support future R&D.
- Significant Clinical Progress: Vir's chronic hepatitis delta program showed encouraging Phase 2 data, with 88% of evaluated patients achieving undetectable virus levels by Week 96, and the company anticipates Phase 3 data from its lead study in Q4 2026, further boosting market confidence.
See More
Superstring Capital Acquires Shares in Vir Biotechnology
- Share Acquisition: Superstring Capital acquired 730,548 shares of Vir Biotechnology in Q1, with an estimated transaction value of $5.82 million, reflecting confidence in the company's future developments.
- AUM Growth: This transaction resulted in a 4.16% increase in Superstring Capital's 13F reportable AUM, indicating that its investment strategy in the biotechnology sector is yielding positive results.
- Strong Financial Position: Vir Biotechnology reported $809.3 million in cash and cash equivalents at the end of Q2, and expects to receive an additional $315 million from its collaboration with Astellas, enhancing its funding for future R&D.
- Clinical Progress: Vir's chronic hepatitis program showed that 88% of patients achieved undetectable virus levels through Week 96 in Phase 2 trials, with pivotal Phase 3 data expected in Q4 2026, potentially leading to significant breakthroughs for the company.
See More
SB Investment Advisers Reduces Stake in Vir Biotechnology
- Share Reduction Details: SB Investment Advisers reported a sale of 2,168,884 shares of Vir Biotechnology in its SEC filing dated May 15, 2026, with an estimated trade value of $17.28 million, indicating a strategic adjustment in its investment approach.
- Market Performance Analysis: As of May 15, 2026, Vir Biotechnology's stock price stood at $8.79, reflecting a 93% increase over the past year, significantly outperforming the S&P 500's approximate 25% gain, showcasing the company's robust market performance.
- Financial Overview: Vir Biotechnology has a market capitalization of $1.48 billion, with a trailing twelve-month revenue of $64.7 million and a net loss of $442.72 million, indicating ongoing challenges in profitability, yet it maintains a strong liquidity position with $809.3 million in cash and investments.
- Strategic Development Dynamics: Despite trimming over 2 million shares, SB Investment Advisers still holds approximately $98 million in Vir, suggesting confidence in the company's long-term potential in oncology and hepatitis, particularly following significant advancements in its partnership with Astellas.
See More
Boxer Capital Increases Stake in Vir Biotechnology
- Share Acquisition: On May 15, 2026, Boxer Capital Management disclosed the purchase of 1,241,000 shares of Vir Biotechnology, valued at approximately $9.89 million, indicating increased confidence in the company's prospects.
- Stake Increase: This transaction raised Boxer Capital's stake in Vir Biotechnology to 2.2%, highlighting its significant interest in the company as reported in the 13F filing.
- Financial Performance: Vir Biotechnology's market value increased by $12.95 million in Q1 2026, despite a net income loss of $442.72 million; however, its stock price surged 100% over the past year, significantly outperforming the S&P 500's 25% increase.
- Future Outlook: Vir Biotechnology reported encouraging Phase 2 data in chronic hepatitis delta, with pivotal Phase 3 trials for its prostate cancer treatment expected in 2027, raising questions about its ability to achieve sustainable commercialization amidst investor scrutiny.
See More
GT Biopharma Initiates Phase 1 Trial of GTB-5550 for Solid Tumors
- Trial Launch: On May 14, 2026, GT Biopharma announced that the first patient has been dosed in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager, marking a significant advancement in treating historically resistant solid tumors.
- Innovative Dosing Method: GTB-5550 is the first TriKE® molecule tested with subcutaneous dosing, administered for five consecutive days in the abdominal area during each four-week cycle, which is expected to enhance patient compliance and reduce treatment-related side effects.
- Broad Tumor Type Coverage: The trial is designed as a basket study encompassing seven solid tumor types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers, indicating the potential applicability of GTB-5550 across multiple difficult-to-treat tumors.
- Strong Market Demand: With prostate and pancreatic cancers historically unresponsive to standard immunotherapies, GTB-5550 is poised to address this significant unmet medical need, enhancing the company's competitiveness in the rapidly evolving immuno-oncology market.
See More
Vicki Sato Sells 22,000 Shares of Vir Biotechnology Stock
- Transaction Overview: Vicki Sato sold 22,000 shares of common stock for approximately $221,000 according to SEC Form 4, retaining 1,078,391 shares post-sale, valued at around $10.78 million, indicating her continued confidence in the company.
- Trading Plan: The sale was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, suggesting that Sato is engaging in routine portfolio management rather than reacting to market fluctuations.
- Ownership Proportion: This transaction represented 2% of Sato's direct holdings, leaving her with approximately 77.5% of her initial position, which underscores her long-term commitment and confidence in the company.
- Company Overview: Vir Biotechnology focuses on developing monoclonal antibodies and RNA-based therapeutics for infectious diseases like COVID-19 and HIV; despite a net loss of $125.7 million in Q1, the company holds $809.3 million in cash and investments, ensuring operational sustainability.
See More
